Aida Pharma Affiliate Developing New Antibiotic
by Richard Daverman, PhD
ChinaBio Today
Aida Pharmaceuticals, Inc. (OTCBB: AIDA) is working on a new wide-spectrum antibiotic that was discovered by its recently acquired affiliate, the Jiangsu Institute of Microbiology Co., Ltd (JSIM). Wetimicin, which belongs to a new generation of amino-glycoside antibiotics, is in Phase I trials. Aida believes the product will have a wider market than its current antibiotic, Etimicin Sulphate. In its various forms, Etimicin Sulphate produced the majority of Aida’s $29 million of revenues in 2007. Etimicin Sulphate belongs to the same family of antibiotics as Wetimicin.
Wetimicin is being tested as a treatment for inflammations (including respiratory infection, urinogenital infection, soft skin tissue infection) and also for infections from trauma and operations. JSIM expects that Wetimicin will prove to be safer and more reliable for children and elderly patients than current antibiotics.
Aida has a controlling interest in JSIM, but does not own it outright. It has a right of first refusal on any drugs that are granted marketing approval by the SFDA.
JSIM began working on the compound in 2000. Aida expects JSIM to begin a Phase II trial of Wetimicin later in 2008.
ChinaBio Today is a regular contributor to BioHealth Investor
______________
ChinaBio Today
Aida Pharmaceuticals, Inc. (OTCBB: AIDA) is working on a new wide-spectrum antibiotic that was discovered by its recently acquired affiliate, the Jiangsu Institute of Microbiology Co., Ltd (JSIM). Wetimicin, which belongs to a new generation of amino-glycoside antibiotics, is in Phase I trials. Aida believes the product will have a wider market than its current antibiotic, Etimicin Sulphate. In its various forms, Etimicin Sulphate produced the majority of Aida’s $29 million of revenues in 2007. Etimicin Sulphate belongs to the same family of antibiotics as Wetimicin.
Wetimicin is being tested as a treatment for inflammations (including respiratory infection, urinogenital infection, soft skin tissue infection) and also for infections from trauma and operations. JSIM expects that Wetimicin will prove to be safer and more reliable for children and elderly patients than current antibiotics.
Aida has a controlling interest in JSIM, but does not own it outright. It has a right of first refusal on any drugs that are granted marketing approval by the SFDA.
JSIM began working on the compound in 2000. Aida expects JSIM to begin a Phase II trial of Wetimicin later in 2008.
ChinaBio Today is a regular contributor to BioHealth Investor
______________
posted by Nico at
5:30 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home